Summary The anti-tumour effect induced by a delayed hypersensitivity response (DHSR) unrelated to the tumour or by intra-tumoural inoculation of BCG was studied with 6 syngeneic mouse tumours. The growth of the tumours was followed i.p. or s.c. in suitably sensitized animals either in the presence or absence of the specific antigen required to elicit a DHSR. In a Winn-type assay the growth of tumour cells admixed with sensitized lymphocytes was also determined with and without the eliciting antigens. In addition, the effect of admixing different amounts of BCG with the tumour cells was studied on the growth of the tumours in vivo. The different tumours varied widely in their susceptibility to growth inhibition by a DHSR reaction and by BCG but their order of sensitivity was the same in all of the tests.
The destruction of some local tumours-principally but not exclusively of the skin-as a result of inducing persistent inflammation by a delayed-type hypersensitivity response (DHSR) (Klein, 1968) , inoculation of vaccinia virus (Hunter-Craig et al., 1970) or intratumoural inoculation of BCG (Morton et al., 1970) was first observed in man. This effect can be mimicked in rodents with some, but not all, syngeneic transplantable tumours. An in vivo anti-tumour action of a DHSR was demonstrated in our laboratory by immunizing mice with BCG and then injecting the eliciting antigen, purified derivative of tuberculin (PPD) either mixed with or given one or two days after, inoculation of tumour cells i.p., i.v., s.c. or i.d. (Alexander, 1973, and Alexander et al., 1981) .
Initially, we ascribed the destruction of tumour cells at the site of a DHSR reaction to activated macrophages (Alexander, 1973) but subsequently found (Parr et al., 1975) in a Winn-type assay, in which leukocytes from an inflammatory site (peritoneal cavity) are added to tumour cells in vitro Correspondence: P. Alexander, CRC Medical Oncology Unit, Southampton General Hospital, Southampton S09
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Received 10 February 1983; accepted 9 June 1983 and the mixture inoculated into mice, that the lymphocytes-and not the macrophages were the principal cytotoxic cells involved. This study raised the possiiMlty that a cytotoxic lymphokine(s) could be the,agent responsible for the destruction of tumour in the midst of an inflammatory reaction.
This investigation addressed itself to the questions: (a) is the mechanism by which a DHSR eliminates a local tumour the same as that responsible for the anti-tumour action of intralesional BCG; and (b) which of the potential antitumour agents present in a DIHSR are responsible for the in vivo anti-tumour effect? Activated macrophages, NK cells, allergized lymphocytes or lymphokines (e.g. lymphotoxin) released when allergized lymphocytes contact the specific antigen are all likely to be present in a lesion induced by a DHSR and all have been shown to be capable of killing tumour cells in vitro, Alexander (1973) , Wolfe et al. (1976) , Granger & Kolb (1968) .
Our approach to this problem was to compare in a series of syngeneic mouse tumours, their susceptibility to inhibition in vivo (i) by a DHSR (in both skin and peritoneal cavity), (ii) by intralesional BCG, and (iii) in a Winn assay using cells from a peritoneal exudate induced by a DHSR. The combined data strongly support the hypothesis that a cytotoxic factor elaborated when T-cells © The Macmillan Press Ltd., 1983 from sensitized animals meet the specific antigen and which has the properties ascribed to lymphotoxin, is responsible for the destruction of certain tumours by both a DHSR and intra-lesional BCG.
Materials and methods

Animals
Ten-week old mice C57/Bl and DBA/2 were supplied by the breeding unit of the Chester Beatty Research Institute. They were fed the usual diet of water and mouse chow ad libitum throughout the experiments.
Tumours
Details of fibrosarcomas FS6, FS1 (C57/B1 mice) and lymphomas L5178Y (DBA/2) and TLX9 (C57/Bl) were given previously (Parr et al., 1973) . FS29 is a benzpyrene; induced fibrosarcoma, whilst FS6M1 is a metastatic line which arose after prolonged passage of FS6. Minimum numbers of tumour cells necessary for 100% tumour incidence (at i.d. site) are given in Table IV . All tumours were adapted to grow in either suspension (lymphomas) or monolayer (fibrosarcomas) culture and were maintained in RPMI 1640 medium supplemented with 10% FBS, sodium pyruvate and L-glutamine. Early storage of the tumour cells in liquid N2 as soon as growth was established in vitro allowed regular returns to the tumour bank after 9-10 passages. Target cells used in cytotoxicity assays were taken from serial passage numbers 3-10.
Chemicals
Freeze-dried BCG vaccine (percutaneous: Glaxo Laboratories Ltd., Greenford, Middlesex, England) contained 1-3 x 108 viable units per ampoule equivalent to 3mg (moist weight) organisms ml-' . 'Immunized with BCG i.p. 14 days prior to inoculation of tumour cells.
there was no effect at all on the growth of the radiation-induced lymphoma TLX9. The magnitude of the response of the other tumours can be roughly quantitated by comparing the size of the inoculum that was rejected in the presence of a DHSR with that needed to produce a tumour in normal mice. A protective factor expressed as the ratio of the number of tumour cells needed to produce tumours in the presence and in the absence of an inflammatory reaction ranges progressively in this series of tumours from greater than 103 for FS6 to 1 (i.e. no protection) for TLX9. Figure 1 shows that the different tumours may be placed in the same order of sensitivity to inhibition of growth by a DHSR either growing i.p. or in an s.c. site. In the Winn test (Figure 2) 
Participation of T-lymphocytes
The involvement of T-cells could be demonstrated for each of the three procedures used to demonstrate in vivo an anti-tumour action associated with inflammation. In the first test system in which 106 FS6 cells mixed with PPD were inoculated i.p. into mice immunized with BCG as described in Table I (Table V) . The composition of the PE cells in mice 14 days after immunization with BCG has been studied by Parr et al. (1977) and found to have 30% Thy 1.2 positive cells which do not adhere to nylon wool even when fractionated in the absence of serum. After fractionation on nylon wool (or by adherence to plastic) 70% of the PE cells are non-adherent but only half of these are positive for Thy 1.2. From Table V it is clear that on a per cell basis the cells which do not adhere to nylon in the absence of serum and of which 90% are T-cells on the basis of being lysed by Thy 1.2 antibody and complement, (Chung et al., 1973) , find that destruction of tumours by intra-lesional BCG requires the presence of mature T-cells. We find ( Table IV) that admixture of BCG is much less effective in preventing the growth of FS6 cells in mice deprived of T-cells both as a result of genetic defect (the nude mouse) or as a result of treatment with the highly effective immunosuppressive agent Cyclosporin A which interferes with the immune response by preventing the production of sensitized T-cells (Bunjes et al., 1982) .
Relative sensitivity in vitro of the different tumours to immunologically non-specific killing by different effectors In vitro cells can be killed in an immunological non-specific manner (i.e. independent of the recognition by T-cells of antigens on their surface) by macrophages (probably by a variety of different mechanisms), stimulated granulocytes, NK cells and by lymphokines, i.e. "lymphotoxin." While it is correct to say that these cytotoxic processes are immunologically non-specific, they are highly selective in that some cells are much more vulnerable than others. The order of sensitivity of different tumour cells is not the same for various types of killing and we therefore compared the susceptibilities in vitro of the tumours used in this investigation to those effector mechanisms which are most likely to be involved in the in vivo antitumour activity of a DHSR and intra-lesional BCG. These were NK cells, granulocytes, macrophages activated by lymphokines (i.e. macrophage-activating activity (MAF) present in supernatants of cultures in which T-cells from BCG sensitized mice were exposed to PPD-Evans, Cox & Alexander, (1973) and the direct cytotoxicity of such supernatants which is due to lymphotoxin (Granger & Kolb, 1968 Figure 2 ). dHuman polymorphs activated by addition of Con A were incubated (at ratio 5 polymorphs: 1 target cell) for 1.5 h . Fig _%Specific 5 "Cr release.
From the results shown in Table V it can be deduced that a cell responsible for initiating tumour destruction in the Winn assay is a radio-resistant allergized T-cell that has been exposed to the approriate antigen. The Winn test data do not allow us to decide whether such a cell is immediately cytotoxic, or whether the effect is caused by a lymphokine. If it is caused by a lymphokine, then this could be directly cytotoxic or it could arm macrophages provided by the host which has been inoculated with the mixture of tumour cells and allergized T-cells that have been exposed to antigen. In the three in vivo situations studied, i.e. inoculation of tumour cells into the site of the DHSR, intra-lesional BCG and the particular Winn test used here, macrophageactivating factor (MAF) will be produced and macrophages, rendered cytotoxic, will be present, yet from the data shown in Table VI these do not appear to contribute significantly to the antitumour action of inflammation. Macrophages armed with MAF are most effective in killing those tumour cells, the growth of which in vivo is least susceptible to inflammation. On the other hand, the direct cytotoxic activity of the lymphokine containing supernatants (i.e. "lymphotoxin") mimicks closely the in vivo response. A detailed study of the cytotoxic action of T-cells and PPD from BCG treated mice and the optimum condition for obtaining "lymphotoxin" activity will be reported subsequently.
The available data are consistent with the hypothesis that the interference by inflammation with local tumour growth is brought about by the formation of lymphotoxin at the site of inflammation. These experiments suggest that it is worthwhile to explore means of making lymphotoxin available systemically to treat disseminated malignant cells. Sensitivity to lymphotoxin is probably not infrequent with human tumours since, when they are present in the skin, many tumours of different histological type have been found to respond to the induction of a DHSR or to intra-lesional BCG.
